Grail’s cancer blood test nears FDA approval as insurance coverage looms

• Widespread insurance coverage could create a $60 billion U.S. market by 2030, based on 120 million adults aged 50+ taking a $500 test annually, with global market potential reaching $150 billion
• A UK trial showed Galleri did not significantly increase early cancer detection overall, but full results indicated a 26% reduction in stage IV diagnoses across 12 deadly cancers by the third screening round
• Only five cancers currently have established U.S. preventive screening guidelines, detecting just 14% of newly diagnosed cancers, while multi-cancer blood tests aim to close this screening gap for over 200 cancer types

Summary: Grail's Galleri Blood Test Nears FDA Approval

Key Development:

A U.S. FDA advisory panel recommended approval for Grail's Galleri multi-cancer blood test, stating its benefits outweigh risks. While the FDA isn't required to follow the recommendation, it typically does, with Wall Street analysts expecting approval in coming months.

Market Opportunity:

• Potential U.S. market: $60 billion annually by 2030 (based on 120 million adults age 50+ taking a $500 test yearly)
• Global market potential: $150 billion
• Realistic U.S. market with 30-50% penetration: $18-30 billion over 5-10 years

Current Market Status:

• Galleri and Abbott's Cancerguard currently marketed as laboratory-developed tests under CLIA
• Not covered by Medicare; patients pay $700-900 out-of-pocket
• FDA approval could enable Medicare coverage starting 2028 under new legislation
• Private insurers (CVS, Humana, UnitedHealth, Cigna, Centene) have not committed to coverage plans

Technology:

• Galleri detects signals for 50+ cancer types via blood test
• Claims 93.4% accuracy identifying cancer origin
• Addresses screening gap: only 5 cancers (breast, cervical, colorectal, prostate, lung) have established U.S. screening guidelines; 14% of new cancers detected through routine screening

Clinical Concerns:

• UK trial showed no significant increase in early detection versus standard care
• However, demonstrated 26% reduction in stage IV diagnoses for 12 deadly cancers by third screening round
• Medical experts cite concerns about false positives, follow-up costs, and anxiety
• Unclear whether tests improve patient outcomes or reduce cancer deaths

Political Support:

Test has backing from the Make America Healthy Again movement associated with Health Secretary Robert F. Kennedy Jr.